Skip to Content

Compugen Ltd CGEN

Morningstar Rating
$0.81 −0.02 (2.86%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CGEN is trading at a 60% discount.
Price
$0.82
Fair Value
$4.83
Uncertainty
Extreme
1-Star Price
$83.58
5-Star Price
$6.65
Economic Moat
Ddd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGEN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.83
Day Range
$0.800.81
52-Week Range
$0.531.49
Bid/Ask
$0.76 / $0.79
Market Cap
$71.20 Mil
Volume/Avg
62,301 / 177,975

Key Statistics

Price/Earnings (Normalized)
Price/Sales
9.37
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
69

Valuation

Metric
CGEN
Price/Earnings (Normalized)
Price/Book Value
1.34
Price/Sales
9.37
Price/Cash Flow
Price/Earnings
CGEN

Financial Strength

Metric
CGEN
Quick Ratio
5.81
Current Ratio
5.81
Interest Coverage
Quick Ratio
CGEN

Profitability

Metric
CGEN
Return on Assets (Normalized)
−37.33%
Return on Equity (Normalized)
−46.13%
Return on Invested Capital (Normalized)
−47.92%
Return on Assets
CGEN

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMsy$438.0 Bil
REGN
Regeneron Pharmaceuticals IncDknhzw$92.5 Bil
VRTX
Vertex Pharmaceuticals IncZsyrbv$91.2 Bil
SGEN
Seagen Inc Ordinary SharesKpdljlj$41.2 Bil
MRNA
Moderna IncTsfxc$30.5 Bil
ARGX
argenx SE ADRFkvqk$27.2 Bil
BNTX
BioNTech SE ADRGbjk$24.2 Bil
ALNY
Alnylam Pharmaceuticals IncYmhqdy$22.2 Bil
BMRN
Biomarin Pharmaceutical IncSkqbzl$17.9 Bil
INCY
Incyte CorpHlxdv$12.4 Bil